These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35258358)

  • 21. Correlation of whole blood hydroxychloroquine concentration with cutaneous lupus erythematosus and factors associated with it: First multicenter, cross-sectional analysis in Malaysia.
    Peh D; Wan Ahmad Kammal WSL; Beh PJ; Yong ACH; Tan WC; Lim AL; Thevarajah S; Stanslas J; How KN
    J Dermatol; 2022 May; 49(5):545-549. PubMed ID: 35067938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus.
    Feldmann R; Salomon D; Saurat JH
    Dermatology; 1994; 189(4):425-7. PubMed ID: 7873836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus.
    Ezra N; Jorizzo J
    Clin Exp Dermatol; 2012 Jun; 37(4):327-34. PubMed ID: 22582908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experience with the use of hydroxychloroquine for the treatment of lupus erythematosus.
    Momose Y; Arai S; Eto H; Kishimoto M; Okada M
    J Dermatol; 2013 Feb; 40(2):94-7. PubMed ID: 23216212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment.
    Jewell ML; McCauliffe DP
    J Am Acad Dermatol; 2000 Jun; 42(6):983-7. PubMed ID: 10827400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hydroxychloroquine does not impair antibody response to 13-valent pneumococcal conjugate vaccine in patients with cutaneous lupus erythematosus-A pilot study.
    Pelka K; Matyja-Bednarczyk A; Wojas-Pelc A; Pastuszczak M
    Dermatol Ther; 2021 Jul; 34(4):e15013. PubMed ID: 34056799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hydroxychloroquine modulates elevated expression of S100 proteins in systemic lupus erythematosus.
    Wakiya R; Kameda T; Ueeda K; Nakashima S; Shimada H; Mansour MF; Kato M; Miyagi T; Miyatake N; Kadowaki N; Dobashi H
    Lupus; 2019 Jun; 28(7):826-833. PubMed ID: 31068068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus.
    Al-Rawi H; Meggitt SJ; Williams FM; Wahie S
    Lupus; 2018 Apr; 27(5):847-852. PubMed ID: 28862574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of smoking on the effectiveness of antimalarial drugs for cutaneous lesions of patients with lupus: assessment in a prospective study].
    Lardet D; Martin S; Truchetet F; Cuny JF; Virion JM; Schmutz JL
    Rev Med Interne; 2004 Nov; 25(11):786-91. PubMed ID: 15501347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Candidate drug replacements for quinacrine in cutaneous lupus erythematosus.
    Yan D; Borucki R; Sontheimer RD; Werth VP
    Lupus Sci Med; 2020 Oct; 7(1):. PubMed ID: 33082164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare.
    Braunstein I; Goodman NG; Rosenbach M; Okawa J; Shah A; Krathen M; Kovarik CL; Luning Prak E; Werth VP
    J Am Acad Dermatol; 2012 Apr; 66(4):571-82. PubMed ID: 21821308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural history of disease activity and damage in patients with cutaneous lupus erythematosus.
    Ker KJ; Teske NM; Feng R; Chong BF; Werth VP
    J Am Acad Dermatol; 2018 Dec; 79(6):1053-1060.e3. PubMed ID: 29969701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Quinacrine in the treatment of cutaneous lupus erythematosus: practical aspects and a case series].
    González-Sixto B; García-Doval I; Oliveira R; Posada C; García-Cruz MA; Cruces M
    Actas Dermosifiliogr; 2010; 101(1):54-8. PubMed ID: 20109393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI).
    Yokogawa N; Kato Y; Sugii S; Inada S
    Mod Rheumatol; 2012 Apr; 22(2):249-55. PubMed ID: 21842436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study.
    Francès C; Cosnes A; Duhaut P; Zahr N; Soutou B; Ingen-Housz-Oro S; Bessis D; Chevrant-Breton J; Cordel N; Lipsker D; Costedoat-Chalumeau N
    Arch Dermatol; 2012 Apr; 148(4):479-84. PubMed ID: 22508872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cutaneous lupus erythematosus: factors related to cutaneous activity and damage in a cohort of 260 patients from A Coruña, Spain.
    Arévalo-Bermúdez MDP; Paradela S; Balboa-Barreiro V; Fonseca E
    Lupus; 2020 Aug; 29(9):1021-1030. PubMed ID: 32539659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of hydroxychloroquine on lupus erythematosus-like skin lesions in MRL/lpr mice.
    Shimomatsu T; Kanazawa N; Mikita N; Nakatani Y; Li HJ; Inaba Y; Ikeda T; Kondo T; Furukawa F
    Mod Rheumatol; 2016 Sep; 26(5):744-8. PubMed ID: 26873035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus erythematosus.
    Masek-Hammerman K; Peeva E; Ahmad A; Menon S; Afsharvand M; Peng Qu R; Cheng JB; Syed J; Zhan Y; O'Neil SP; Pleasic-Williams S; Cox LA; Beidler D
    Clin Exp Immunol; 2016 Feb; 183(2):258-70. PubMed ID: 26376111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature.
    Chasset F; Francès C; Barete S; Amoura Z; Arnaud L
    J Am Acad Dermatol; 2015 Apr; 72(4):634-9. PubMed ID: 25648824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discontinuation of antimalarial drugs in systemic lupus erythematosus.
    Wang C; Fortin PR; Li Y; Panaritis T; Gans M; Esdaile JM
    J Rheumatol; 1999 Apr; 26(4):808-15. PubMed ID: 10229401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.